摘要
目的:分析我院急性冠脉综合征患者使用头孢哌酮/舒巴坦的安全性,为临床合理用药提供参考。方法:通过查阅中国知识资源总库(CNKI1994-2011年)中收录的使用头孢菌素类抗生素出现血小板减少症、凝血时间延长的病例报道,结合我院急性冠脉综合征患者使用头孢哌酮/舒巴坦的情况进行分析。结果:纳入本研究的45篇文献中,有关使用头孢哌酮/舒巴坦出现血小板减少症、凝血时间延长的报道有28篇,计52例。文献证据表明,头孢哌酮/舒巴坦在头孢菌素类抗生素中引发出血的倾向最高;经查阅我院2011年1-7月心血管内科241份使用抗菌药物的急性冠脉综合征患者,显示选择头孢哌酮/舒巴坦抗感染治疗的比例达72.61%。结论:我院急性冠脉综合征患者的抗感染治疗应慎用头孢哌酮/舒巴坦;确有必要使用头孢哌酮/舒巴坦的患者,建议每5天做1次血小板计数及凝血时间监测。
OBJECTIVE：To provide reference for clinical rational drug use through evaluating the safety of patients with acute coronary syndrome treated by cefoperazone/sulbactam in our hospital.METHODS：We collected the case reports from Chinese knowledge source（CNKI,1994-2011）,in which patients suffered from thrombocytopenia and prolonged coagulation time after using cephalosporins antibiotics,and analyzed the situation of patients treated with cefoperazone/sulbactam in our hospital.RESULTS：Among 45 literatures,28 reported thrombocytopenia and prolonged coagulation time appeared after using cefoperazone/sulbactam,a total of 52 cases.Literature indicated that the bleeding tendency of using cefoperazone/sulbactam was the highest in all cephalosporin antibiotics.Through inspecting 241 case histories of using antimicrobial drugs for acute coronary syndrome from Jan.to Jul.in 2011,the rate of using cefoperazone/sulbactam reached 72.61%.CONCLUSION：It should be prudent to use cefoperazone/sulbactam in patients with acute coronary syndrome.If it is really necessary to use cefoperazone/sulbactam,we suggest to carrying out a platelet count and clotting time monitoring every five days.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第46期4382-4384,共3页
China Pharmacy
